Welcome to our dedicated page for Xtant Medical SEC filings (Ticker: XTNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xtant Medical Holdings, Inc. (XTNT) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including current reports, proxy statements, and financial updates filed with the U.S. Securities and Exchange Commission. Xtant is a global medical technology company focused on orthobiologics for chronic and surgical wound care and sports medicine markets, as well as spinal implant systems for spinal and other orthopedic conditions, and its filings offer detailed insight into how this business is governed and financed.
Among the key documents available are Form 8-K current reports, where Xtant discloses material events. For example, an 8-K dated December 3, 2025 describes the completion of the sale of certain Coflex and CoFix spinal implant assets and all shares of Paradigm Spine GmbH, its international hardware business, to Companion Spine entities, along with related use of proceeds and pro forma financial information. Other 8-Ks report quarterly financial results, the use of non-GAAP adjusted EBITDA, changes to the Board of Directors, the establishment of the annual meeting date, and risk factor updates linked to strategic transactions.
Investors can also review definitive proxy statements on Schedule 14A, such as the document filed on September 15, 2025. That proxy statement outlines the agenda for the annual meeting of stockholders, including director elections, ratification of the independent registered public accounting firm, an amendment to the 2023 Equity Incentive Plan, and advisory votes on executive compensation and its frequency. It also describes corporate governance guidelines, board structure, director and executive compensation, and ownership information.
Through Stock Titan, these XTNT filings are updated as they appear on EDGAR and are accompanied by AI-powered summaries designed to explain the main points in accessible language. Users can quickly see what each filing covers—such as divestiture terms, debt prepayments, equity plan changes, or non-GAAP metric definitions—without reading every page in full.
For those tracking financial performance and capital structure, the filings include condensed consolidated balance sheets, income statement data, and discussions of liquidity, debt arrangements, and credit facility consents. Governance-focused readers can examine voting results from the annual meeting, details of equity incentive plan amendments, and disclosures about significant shareholders and board composition.
By using this XTNT filings page, investors, analysts, and researchers can navigate Xtant Medical’s regulatory history, understand the implications of its asset sales and biologics-focused strategy, and interpret recurring topics such as non-GAAP adjusted EBITDA and risk factors, with AI tools helping to highlight the most important elements in each submission.
Xtant Medical Holdings reported improved operating results for the quarter ended June 30, 2025 with total revenue of $35.4 million, up 18% from the prior-year quarter, driven by higher orthobiologics sales and $5.0 million of license revenue recognized in the quarter. Gross profit rose to $24.3 million, lifting gross margin to 68.6% from 62.1% a year earlier, reflecting better sales mix, scale and lower product costs. The company posted net income of $3.55 million for the quarter, reversing a prior-year loss.
On the balance sheet, total assets increased to $103.5 million and stockholders' equity to $48.5 million. Cash and restricted cash at period end totaled $7.04 million. The company remains levered with a $22.3 million term loan (net of issuance costs) and a $12.0 million outstanding on its revolving line of credit, and it reported compliance with credit covenants. Subsequent to period end, Xtant entered agreements to sell its Coflex/CoFix U.S. business for $17.5 million (with a non-refundable $2.5 million deposit received) and Paradigm Spine GmbH for $1.7 million, both closings contingent on buyer financing and subject to customary adjustments.
Xtant Medical Holdings, Inc. announced its financial results for the three and six months ended June 30, 2025 and furnished a related press release and investor presentation as exhibits to this Current Report.
The company explained its use of a non-GAAP adjusted EBITDA metric, defined as net income (loss) before depreciation and amortization, interest and tax benefit (expense), and further adjusted to add back or exclude separation-related expenses, non-cash compensation, divestiture/acquisition-related expenses, acquisition-related fair value adjustments, and unrealized foreign currency translation gains or losses. The press release reconciles this non-GAAP measure to GAAP net income. The filing also discloses a pending divestiture of its non-core Coflex/CoFix spinal implants and international business and notes that furnished materials are provided pursuant to Regulation FD.
Xtant Medical Holdings, Inc. director Tyler Lipschultz filed an initial insider ownership report on Form 3. The filing states that, as of the event date of August 1, 2025, no securities of Xtant Medical Holdings, Inc. are beneficially owned.
Xtant Medical Holdings, Inc. established November 7, 2025 as the date for its 2025 Annual Meeting of Stockholders and said it anticipates printing the proxy statement on or about September 12, 2025 and mailing or making it available commencing on or about September 15, 2025. The company noted the meeting date changed by more than 30 days from last year.
Because of that change, stockholder proposals under Rule 14a-8 must be received at the company’s principal executive offices by the close of business on August 18, 2025. Other stockholder proposals and director nominations under the Bylaws also must be delivered in writing to the Corporate Secretary by August 18, 2025. Stockholders seeking to solicit proxies for alternative director nominees must comply with the universal proxy requirements, including providing written notice no later than September 8, 2025.
Abhinav Jain filed an SEC Form 3 reporting his initial statement of beneficial ownership for Xtant Medical Holdings, Inc. (XTNT) related to an 08/01/2025 event. The filing identifies Mr. Jain as a Director and provides his address. The form explicitly states No securities are beneficially owned by the reporting person. The document is signed by an attorney-in-fact on 08/08/2025.